• Unsuccessful lung cancer drugs U.S. 1998-2014 | Statistic

Health & Pharmaceuticals›
Pharmaceutical Products & Market›
Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

Number of unsuccessful lung cancer drugs in the United States from 1998 to 2014

Loading statistic...

© Statista 2017

Show further information

Show sources information

About This Statistic

This statistic depicts the number of unsuccessful lung cancer drugs that were developed in the United States from 1998 to 2014. In 2011, there were 13 unsuccessfully developed lung cancer drugs. Since 1998, there have been 167 total medicines being developed for lung cancer that were discontinued, suspended, or had no development reported and 10 approved medications.

Special Functions

Download as ...

Options

Top cancer drugs based on revenue worldwide 2015

Top cancer drugs based on revenue worldwide 2015

Unsuccessful developing brain cancer drugs in the U.S. 1998-2014

Unsuccessful developing brain cancer drugs in the U.S. 1998-2014

Number of cancer drugs in development in the U.S. 2005-2015

Number of cancer drugs in development in the U.S. 2005-2015

Top cancer drugs paid by Medicare Part B by sales price per dosage 2014

Top cancer drugs paid by Medicare Part B by sales price per dosage 2014

Expensive cancer drugs by annual Medicare payments in the U.S. 2014

Expensive cancer drugs by annual Medicare payments in the U.S. 2014

Age-standardized death rate of lung cancer among Canadian males 1988-2017

Age-standardized death rate of lung cancer among Canadian males 1988-2017

Statista Accounts: Access All Statistics. Starting from $588 / Year

Prices & Access

Statistics on "Clinical trials"

R&D overview

The most important statistics

Total global spending on pharmaceutical research and development from 2008 to 2022 (in billion U.S. dollars)Total global pharmaceutical R&D spending 2008-2022
Percentage of spending on research and development of total revenue from 2013 to 2015, by industrial sector*Industry sectors - expenditure on research and development 2013-2015
Selected top pharmaceutical R&D projects based on net present value (NPV) as of May 2017 (in million U.S. dollars)* Top pharmaceutical R&D projects based on net present value May 2017
Research and development expenditure of total U.S. pharmaceutical industry from 1995 to 2015 (in billion U.S. dollars)*Research and development expenditure: U.S. pharmaceutical industry 1995-2015
Pharmaceutical research and development spending in selected European countries in 2015 (in million euros)Research and development in European pharmaceutical industry by country 2015
Total clinical research funding by the National Institutes for Health (NIH) from FY 2013 to FY 2018 (in million U.S. dollars)Total clinical research funding by National Institutes for Health 2013-2018

Top R&D companies

The most important statistics

Global top 10 pharmaceutical companies based on projected R&D spending in 2022 (in billion U.S. dollars)Global top pharmaceutical companies based on R&D spending 2022
World's top 50 pharmaceutical and biotechnology companies based on R&D intensity in 2015Top 50 global pharmaceutical and biotech companies by R&D intensity in 2015
World's top 50 pharmaceutical and biotechnology companies based on 3-year R&D spending growth until 2015*Top pharmaceutical companies in R&D spending growth for 3 years until 2015
Number of patients who took part in clinical trials for pharmaceutical company Roche from 2009 to 2016*Roche: participation of patients in clinical trials 2009-2016
Top global clinical research organizations (CROs) based on 2016 revenue (in million U.S. dollars)Leading global clinical research organizations based on revenue 2016
Investments made by clinical research organizations (CROs) from 2009 to 2014, by phase (in billion U.S. dollars)Investments made by clinical research organizations by phase 2009-2014

Clinical studies

The most important statistics

Complexity of clinical trials compared in 2001-2005 and 2011-2015Comparison between the complexity of clinical trials 2001-2015
Increase in clinical trials' complexity between 2001-2005 and 2011-2015Increase in clinical trials' complexity 2001-2015
Number of registered clinical studies worldwide by location as of August 2017Number of registered clinical studies by location worldwide 2017
Percentage of registered clinical studies worldwide by location as of August 2017Percent of registered clinical studies worldwide by location 2017
Percentage of registered recruiting clinical studies worldwide by location as of August 2017Share of recruiting clinical studies worldwide by location 2017
Total number of registered clinical studies worldwide since 2000 (as of August, 2017)*Total number of registered clinical studies worldwide since 2000
Total number of registered clinical studies with posted results worldwide since 2009 (as of August 2017)*Total number of registered clinical studies with posted results worldwide 2009-2017

Success rates

The most important statistics

Probability of success for drugs in the U.S. in different development phases between 2006 and 2015U.S. drug development Phase success rates 2006-2015
Probability of Phase II success for new drugs in select disease areas in the U.S. between 2006 and 2015U.S. drug development Phase II success rates 2006-2015, by disease area
The probability of Phase III success for new drugs in select disease areas in the U.S. between 2006 and 2015U.S. drug development Phase III success rates from 2006 to 2015, by disease area
Probability of success for oncology vs non-oncology drugs in the U.S. in the different development phases from 2006 to 2015U.S. development Phase success rates for oncology and non oncology drugs 2006-2015
Probability of success for new drugs in the U.S. by development phase between 2006 and 2015, by drug classification U.S. drug development Phase success rates, by drug classification 2006-2015
Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2006 and 2015U.S. development phase success rates for drugs with and without biomarkers 2006-2015

Costs

The most important statistics

Cost of developing a drug in the U.S. from the 1970s until today (in million U.S. dollars)*Pharmaceuticals: cost of drug development in the U.S. since 1975
Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*Leading orphan drugs based on R&D phase III cost 2015
Average per-study costs by trial phase as of 2014 (in million U.S. dollars)*Average per-study costs by trial phase
Total per-study costs by clinical trial phase and therapeutic area as of 2014 (in million U.S. dollars)Total per-study costs by clinical trial phase and therapeutic area
Clinical trial costs by selected cost component and clinical phase as of 2014 (in U.S. dollars)*Clinical trial costs by select component and phase
Average biopharmaceutical clinical trial cost per patient in the United States in 2013, by selected conditionAverage per-patient clinical trial costs in U.S. 2013, by selected condition
Average cost per patient in biopharmaceutical clinical trials in the United States in 2013, by phaseAverage per-patient biopharmaceutical clinical trial costs in the U.S. 2013, by phase

Approvals, launches, setbacks

The most important statistics

Number of new molecular entities launched in the U.S. from 2003 to 2015Number of new drugs launched in the U.S. 2003-2015
Number of new chemical or biological entities developed between 1992 and 2016, by region of originPharmaceutical industry - number of new substances 1992-2016
Number of first world new molecular entities launched from 2004 to 2015First world new molecular entities launched 2004-2015
Number of first premarket approvals (PMA/HDE) granted by the FDA for medtech products from 2005 to 2016FDA first premarket approvals for medtech products granted 2005-2016
Time from NDA/BLA filings for new drugs to FDA approval in select disease areas in the U.S. between 2006 and 2015NDA/BLA filing to FDA approval times for new drugs in select disease areas 2006-2015
Number of unsuccessful Alzheimer’s drugs in development in the U.S. from 1998 to 2014Number of unsuccessful Alzheimer’s drugs in development in the U.S. 1998-2014
Number of unsuccessful melanoma drugs in development in the United States from 1998 to 2014Unsuccessful developing melanoma drugs in the U.S. 1998-2014
Number of unsuccessful lung cancer drugs in the United States from 1998 to 2014Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

Statista for Your Company: The Research and Analysis Tool

Product Film
Statistics
Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Google

Samsung

Unilever

Procter and Gamble

Adobe

Telekom

PayPal

Otto

Further Content: Statistics, Studies, and Topic Pages

Statistics

Topics

Studies

Our Business Solutions: Save Time and Money

only

$588^*

per year

Your advantages

Full access to all our statistics
Download as XLS, PDF & PNG
Relevant data: complete source information

All functions of our platform illustrated face-to-face

Learn how Statista supports your company
Extensive tour across the whole portal
Personal guidance by our support team

Request webinar

The knowledge database for your company

All functions of the Premium Account
Access to dossiers, forecasts and studies
Access to our international database
Publishing rights and other exclusive functions

* All products require an annual contract.
Prices do not include sales tax
(New York residents only).

	Basic Account	Instant Access Premium Account
Our services Click the question mark for further information	Free	$49 per month* (billed annually)
Basic statistics
Premium statistics

Graph download
Download PDF
Excel download
	Register	Purchase now

*Duration: 12 months, billed annually, single license